Organization
Shanghai Chest Hospital, Jiaotong University
11 abstracts
Abstract
First-line sintilimab combined with platinum-based chemotherapy in extensive stage small cell lung cancer: A phase II study and post-hoc biomarker analysis.Org: Shanghai Chest Hospital, Jiaotong University,
Abstract
MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy.Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University School of Medicine,
Abstract
Interim results from a prospective multicenter phase II trial of stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC trial).Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
Effect of RIPK3 on non-canonical PANoptosis to suppress anti-tumor immunity in lung cancer.Org: Shanghai Chest Hospital, Jiaotong University,
Abstract
Preliminary results of a randomized controlled, open-label, multi-center phase II study of camrelizumab combined with chemotherapy followed by concurrent chemoradiotherapy and camrelizumab consolidation therapy versus standard chemoradiotherapy as first-line treatment for limited-disease small cell lung cancer.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shanghai Pulmonary Hospital, Shanghai, China, Tongji University School of Medicine, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Pulmonary and Critical Care Medicine,
Abstract
IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04).Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, The Third Affiliated Hospital Of Qiqihar Medical University, Shandong Provincial Institute of Cancer Prevention and Treatment, Henan Cancer Hospital, Shanghai Lung Cancer Center,
Abstract
Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.Org: Dana-Farber Cancer Institute, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Bristol Myers Squibb, Institut Curie, Saint Cloud, France, McGill University Health Center,
Abstract
A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.Org: Lung Cancer Center, Shanghai Chest Hospital, Jiaotong University, Zhujiang Hospital of Southern Medical University, Guangzhou, China, Department of Biotherapy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China,
Abstract
Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in patients with previously untreated MET-amplified locally advanced/metastatic non-squamous non-small cell lung cancer (NSQ NSCLC).Org: AbbVie Inc., North Chicago, IL, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.Org: Shanghai Pulmonary Hospital, Shanghai, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Bengbu Medical College, Shanghai Chest Hospital, Jiaotong University,
Abstract
Personalized circulating tumor DNA (ctDNA) analysis in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,